The full result from Eisai’s large, global phase 3 confirmatory Clarity AD clinical study of lecanemab – an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of ...

Eisai & Biogen update on regulatory review of MAA for lecanemab for early Alzheimer’s disease by the European Commission: Tokyo Wednesday, April 2, 2025, 16:00 Hrs [IST] Eisai C ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the European Commission (EC) has decided to refer ...

在人类与疾病的漫长斗争中，阿尔茨海默病（Alzheimer’s disease，AD）无疑是一座难以逾越的高山。时间回溯到1901年，德国法兰克福的阿洛伊斯·阿尔茨海默医生接诊了一位举止异常的女性患者。她答非所问、胡言乱语，仿佛被困在自己构建的迷雾之中，无法理解 ...

Transport at Nanoscale Interfaces Laboratory, Swiss Federal Laboratories for Materials Science and Technology, CH-8600 Dübendorf, Switzerland ...

Department of Neurology, Postgraduate training base Alliance of Wenzhou Medical University (Wenzhou People’s Hospital), Wenzhou, China Background: Lecanemab and Aducanumab are two novel anti-amyloid ...

It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Department of Chemical Engineering and Biotechnology, University of Cambridge, Philippa Fawcett Drive, Cambridge CB3 0AS, U.K. Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, U.K.

It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Since 2005, BioArctic has a long ...

Department of Neurology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China Background: Lecanemab is a humanized murine IgG1 antibody. Recent Phase 3 clinical trials have ...